Efekti resveratrola na profile lipida i enzime jetre kod pacijenata sa metaboličkim sindromom i srodnim poremećajima: sistematski pregled i meta-analiza randomiziranih kontroliranih studija.
Lipids in health and disease
Sažetak istraživanja
Pozadina Postoje trenutna ispitivanja koja istražuju efekat suplementacije resveratrolom na profile lipida i enzime jetre među pacijentima sa metaboličkim sindromom (MetS) i srodnim poremećajima; međutim, njihovi nalazi su kontroverzni. Ovaj sistematski pregled i meta-analiza imali su za cilj da utvrde efekte suplementacije resveratrolom na profile lipida i jetrenih enzima kod pacijenata sa MetS-om i srodnim poremećajima.
Metode Do novembra 2018. izvršili smo sveobuhvatnu pretragu sledećih onlajn baza podataka: Cochrane Library, PubMed, Embase i Web of Science. Relevantni članci su ocijenjeni za kvalitet studija korištenjem Cochrane alata za rizik od pristrasnosti.
Rezultati Od 2459 citata, 31 članak je bio prikladan za uključivanje u trenutnu metaanalizu. Objedinjeni rezultati su pokazali da upotreba resveratrola značajno smanjuje ukupni holesterol [ponderisana srednja razlika (WMD) = - 7,65 mg/dL; 95% CI, - 12,93, - 2,37; P 2 : 83,4%] i povećane koncentracije gama-glutamil transferaze (GGT) (WMD = 1,76 U/l; 95% CI, 0,58, 2,94; P 2 : 20,1%). Nismo pronašli značajan efekat suplementacije resveratrolom na trigliceride (WMD = - 5.84 mg/dL; 95% CI, - 12.68, 1.00; P = 0.09; I 2 : 66.8%), LDL- (WMD = -2.90 mg/dL; -85% CI., 95% PCI., 95% 0,47; I 2 : 96,0%), HDL-holesterol (WMD = 0,49 mg/dL; 95% CI, - 0,80, 1,78; P = 0,45; I 2 : 74,0%), alanin aminotransferaza (ALT), -4UMD = -0.6Cl9. 3,41; P = 0,93; I 2 : 79,6%) i koncentracije aspartat aminotransferaze (AST) (WMD = -0,34 U/l; 95% CI, - 2,94, 2,27; P = 0,80; I 2 : 88,0%).
Zaključci Ova meta-analiza je pokazala da suplementacija resveratrola među pacijentima sa MetS i srodnim poremećajima značajno smanjuje ukupni holesterol i povećava koncentraciju GGT, ali nije utjecala na koncentracije triglicerida, LDL-, HDL-holesterola, ALT i AST. Ovi podaci sugeriraju da resveratrol može imati potencijalni kardio-protektivni učinak kod pacijenata sa MetS i srodnim poremećajima.
Prikaži originalni naslov i sažetak na engleskom
The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.
Background There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders.
Methods We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool.
Results Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = - 7.65 mg/dL; 95% CI, - 12.93, - 2.37; P 2 : 83.4%] and increased gamma-glutamyl transferase (GGT) concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; P 2 : 20.1%). We found no significant effect of resveratrol supplementation on triglycerides (WMD = - 5.84 mg/dL; 95% CI, - 12.68, 1.00; P = 0.09; I 2 : 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, - 10.88, 5.09; P = 0.47; I 2 : 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, - 0.80, 1.78; P = 0.45; I 2 : 74.0%), alanine aminotransferase (ALT) (WMD = -0.14 U/l; 95% CI, - 3.69, 3.41; P = 0.93; I 2 : 79.6%), and aspartate aminotransferase (AST) (WMD = -0.34 U/l; 95% CI, - 2.94, 2.27; P = 0.80; I 2 : 88.0%) concentrations.
Conclusions This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.
Izvorni podaci
- DOI
- 10.1186/s12944-020-1198-x
- PMID
- 32066446
- PMCID
- PMC7026982
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom